| Literature DB >> 35629255 |
Uros Bumbasirevic1,2, Nebojsa Bojanic1,2, Tatjana Simic2,3,4, Bogomir Milojevic1,2, Marko Zivkovic1, Tijana Kosanovic5, Boris Kajmakovic1,2, Aleksandar Janicic1,2, Otas Durutovic1,2, Milan Radovanovic1,2, Veljko Santric1,2, Milica Zekovic6, Vesna Coric2,3.
Abstract
Sustained and dysregulated inflammation, concurrent tumor-induced immune suppression, and oxidative stress are profoundly involved in cancer initiation, presentation, and perpetuation. Within this prospective study, we simultaneously analyzed the preoperative indices of systemic inflammatory response and the representative byproducts of oxidative DNA, protein, and lipid damage with the aim of evaluating their clinical relevance among patients diagnosed with testicular germ-cell tumors (GCT). In the analytical cohort (n = 88, median age 34 years), neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and C-reactive protein (CRP) were significantly altered in patients with a higher tumor stage (p < 0.05). Highly suggestive correlations were found between NLR, dNLR, and SII and modified nucleoside 8-OHdG. CRP and albumin-to-globulin ratio (AGR) significantly correlated with thiols group level and maximal tumor dimension (p < 0.05). Based on receiver operating characteristic (ROC) curve analyses, all the evaluated pre-orchiectomy inflammation markers demonstrated strong performance in predicting metastatic disease; optimal cut-off points were determined for each indicator. Although further large-scale studies are warranted, inflammatory and redox indices may both complement the established tumor markers and standard clinicopathological prognostic variables and contribute to enhanced personalized risk-assessment among testicular GCT patients.Entities:
Keywords: inflammation; oxidative stress; redox biomarkers; systemic inflammatory response; testicular germ-cell tumors
Year: 2022 PMID: 35629255 PMCID: PMC9143453 DOI: 10.3390/jpm12050833
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
The characteristics of patients with testicular GCT.
| Parameters | Patients with Testicular GCT, n = 88 |
|---|---|
| Age (years) | 34 (19–54) 1 |
| Charlsoncomorbidity index, CCI | 0 (0–1) 1 |
| Body mass index, n (%) 2 | 24.9 (17.6–36.1) 1 |
| <30 kg/m2 | 73 (88) |
| >30 kg/m2 | 10 (12) |
| Smoking status, n (%) 2 | |
| Non-smokers | 36 (44) |
| Smokers | 45 (56) |
| Tumor type, n (%) | |
| Seminoma | 52 (59) |
| Non-seminoma | 36 (41) |
| Clinical stage, n (%) | |
| I | 61 (69) |
| II | 18 (21) |
| III | 9 (10) |
1 Median (range); 2 Obese patients were characterized as individuals with a body mass index (BMI) above 30 kg/m2, whereas smokers were characterized as individuals who were engaged in dailysmoking during any 60-day period, prior to the study onset.
The difference in preoperative inflammatory and redox biomarkers between testicular GCT patients at lower and higher tumor stages.
| Laboratory Parameter | Stage I | Stages II + III | |
|---|---|---|---|
| Neutrophils (n × 109/L) | 4.55 (1.80–13.00) | 5.20 (2.70–12.22) | 0.077 |
| Lymphocytes (n × 109/L) | 1.90 (1.10–3.00) | 1.60 (0.40–3.32) | 0.183 |
| NLR | 2.28 (0.72–11.82) | 3.28 (1.65–16.00) | 0.005 * |
| dNLR | 1.71 (0.58–4.64) | 2.18 (1.18–5.77) | 0.031 * |
| Platelets (n × 109/L) | 234.00 (102.00–412.00) | 260.00 (148.00–562.00) | 0.177 |
| PLR | 123.68 (67.27–283.64) | 163.50 (51.61–640.00) | 0.008 * |
| SII (×109/L) | 533.33 (145.71–3687.27) | 824.26 (268.39–4096.00) | 0.001 * |
| SIRI (×109/L) | 1.06 (0.29–16.36) | 1.65 (0.58–6.42) | 0.001 * |
| Monocytes (n × 109/L) | 0.48 (0.10–1.30) | 0.50 (0.30–1.45) | 0.117 |
| LMR | 4.20 (0.85–13.00) | 3.20 (1.00–5.33) | 0.001 * |
| CRP (mg/L) | 0.80 (0.20–301.00) | 2.45 (0.20–197.50) | 0.008 * |
| AGR | 1.84 (1.23–2.78) | 1.62 (0.88–2.35) | 0.009 * |
| 8-OHdG (ng/mL) | 9.25 (5.07–49.50) | 8.51 (4.29–16.48) | 0.373 |
| Thiol groups (ng/mL) | 9.65 (4.98–218.86) | 10.16 (5.93–14.89) | 0.914 |
| MDA (ng/mL) | 94.01 (41.02–302.85) | 98.02 (55.34–372.06) | 0.208 |
NLR—neutrophil-to-lymphocytes ratio; dNLR—derived neutrophil-to-lymphocyte ratio (formula: neutrophil/(WBC-neutrophil)); PLR—platelet-to-lymphocyte ratio; SII—systemic immune-inflammation index (formula: neutrophil × platelet/lymphocyte); SIRI—systemic inflammation response index (formula: neutrophil × monocyte/lymphocyte); LMR—lymphocyte-to-monocyte ratio; CRP—C-reactive protein; AGR—serum albumin/(serum total protein-serum albumin); 8-OHdG—8-hydroxy-2′-deoxyguanosine; MDA—malondialdehyde; * p < 0.05.
Receiver operating characteristics (ROC) curve analysis for pre-orchiectomy inflammatory indices’ performance in predicting metastatic disease among patients diagnosed with testicular GCT.
| Inflammatory Index | Cut-Off Point | AUC | CI | Specificity (%) | Sensitivity (%) | |
|---|---|---|---|---|---|---|
| NLR | 2.685 | 0.691 | 0.05 * | 0.573–0.809 | 67.79 | 70.37 |
| dNLR | 1.775 | 0.646 | 0.031 * | 0.527–0.765 | 57.62 | 70.37 |
| PLR | 160.170 | 0.680 | 0.008 * | 0.539–0.820 | 86.44 | 55.55 |
| LMR | 4.145 | 0.730 | 0.001 * | 0.618–0.842 | 50.84 | 85.18 |
| SII (×109/L) | 683.21 | 0.714 | 0.001 * | 0.549–0.836 | 66.10 | 70.37 |
| SIRI (×109/L) | 1.005 | 0.723 | 0.001 * | 0.612–0.835 | 47.45 | 88.88 |
| CRP (mg/L) | 2.100 | 0.684 | 0.008 * | 0.549–0.819 | 80.76 | 65.38 |
| AGR | 1.530 | 0.695 | 0.009 * | 0.554–0.838 | 93.18 | 44.82 |
NLR—neutrophil-to-lymphocytes ratio; dNLR—derived neutrophil-to-lymphocyte ratio (formula: neutrophil/(WBC-neutrophil)); PLR—platelet-to-lymphocyte ratio; SII—systemic immune-inflammation index (formula: neutrophil × platelet/lymphocyte); SIRI—systemic inflammation response index (formula: neutrophil × monocyte/lymphocyte); LMR—lymphocyte-to-monocyte ratio; CRP—C-reactive protein; AGR—serum albumin/(serum total protein-serum albumin); AUC—area under the curve; CI—confidence interval; * p < 0.05.
Figure 1Graphical presentation of receiver operating characteristic (ROC) curve analysis for preoperative inflammatory indices’ performance in predicting metastatic disease among patients diagnosed with testicular GCT.
Correlation of preoperative inflammatory and redox biomarkers in testicular GCT patients.
| Laboratory Parameter | 8-OHdG (ng/mL) | Thiol Groups (µmol/g) | MDA (ng/mL) |
|---|---|---|---|
| Neutrophils (n × 109/L) | 0.157/0.172 | −0.173/0.115 | 0.050/0.666 |
| Lymphocytes (n × 109/L) | −0.142/0.217 | −0.142/0.197 | −0.062/0.595 |
| NLR | 0.210/0.067 | −0.069/0.531 | 0.153/0.187 |
| dNLR | 0.214/0.061 | −0.062/0.575 | 0.130/0.262 |
| Platelets (n × 109/L) | 0.004/0.974 | −0.183/0.096 | 0.088/0.450 |
| PLR | 0.132/0.252 | 0.000/0.997 | 0.194/0.094 |
| SII (×109/L) | 0.209/0.068 | −0.118/0.299 | 0.182/0.116 |
| SIRI (×109/L) | 0.144/0.210 | −0.129/0.243 | 0.101/0.385 |
| Monocytes (n × 109/L) | −0.078/0.499 | −0.132/0.233 | −0.080/0.493 |
| LMR | −0.115/0.320 | 0.003/0.975 | −0.094/0.417 |
| CRP (mg/L) | 0.109/0.361 | −0.234/0.042 * | −0.049/0.688 |
| AGR | −0.041/0.753 | 0.278/0.025 * | 0.002/0.987 |
NLR—neutrophil–to-lymphocytes ratio; dNLR—derived neutrophil-to-lymphocyte ratio (formula: neutrophil/(WBC-neutrophil)); PLR—platelet-to-lymphocyte ratio; SII—systemic immune-inflammation index (formula: neutrophil × platelet/lymphocyte); SIRI—systemic inflammation response index (formula: neutrophil × monocyte/lymphocyte); LMR—lymphocyte-to-monocyte ratio; CRP—C reactive protein; AGR—serum albumin/(serum total protein-serum albumin); 8-OHdG—8-hydroxy-2′-deoxyguanosine; MDA—malondialdehyde; * p < 0.05.
Correlation of preoperative inflammatory and redox biomarkers with tumor maximal dimension in testicular GCT patients.
| Laboratory Parameter | Tumor Maximal Dimension |
|---|---|
| Neutrophils (n × 109/L) | 0.175/0.107 |
| Lymphocytes (n × 109/L) | −0.038/0.730 |
| NLR | 0.174/0.110 |
| dNLR | 0.173/0.110 |
| Platelets (n × 109/L) | 0.018/0.869 |
| PLR | −0.004/0.971 |
| SII (×109/L) | 0.104/0.339 |
| SIRI (×109/L) | 0.120/0.273 |
| Monocytes (n × 109/L) | 0.094/0.389 |
| LMR | −0.041/0.711 |
| CRP (mg/L) | 0.246/0.030 * |
| AGR | −0.263/0.031 * |
| 8-OHdG (ng/mL) | 0.040/0.729 |
| Thiol groups(ng/mL) | 0.064/0.556 |
| MDA (ng/mL) | 0.160/0.162 |
NLR—neutrophil–to-lymphocytes ratio; dNLR—derived neutrophil-to-lymphocyte ratio (formula: neutrophil/(WBC-neutrophil)); PLR—platelet-to-lymphocyte ratio; SII—systemic immune-inflammation index (formula: neutrophil × platelet/lymphocyte); SIRI—systemic inflammation response index (formula: neutrophil × monocyte/lymphocyte); LMR—lymphocyte-to-monocyte ratio; CRP—C reactive protein; AGR—serum albumin/(serum total protein-serum albumin); 8-OHdG—8-hydroxy-2′-deoxyguanosine; MDA—malondialdehyde; * p < 0.05.